Treatment of Ocular Myasthenia Gravis

Current Treatment Options in Neurology, 11/01/2011

Haines SR et al. – Topical agents may be useful as additional therapy for mild or moderate ptosis. Nonpharmacologic treatments include occlusive devices, prisms, eyelid supports, contact lenses, and (in long-standing, stable cases) strabismus surgery or eyelid elevation surgery.

  • Treatment of ocular MG is aimed at relieving the symptoms of ptosis and diplopia, as well as preventing the development of generalized MG symptoms.
  • Immune suppression with steroids is often the main therapy.
  • Steroid doses must be increased slowly because of a risk of precipitating myasthenic crisis.
  • After achieving the highest target dose, steroids are then slowly tapered down to the lowest effective dose.
  • Often, acetylcholinesterase inhibitors such as pyridostigmine and neostigmine are also employed to help control symptoms.
  • When steroids are contraindicated, acetylcholinesterase inhibitors can be tried as the primary therapy.
  • Steroid-sparing agents such as azathioprine and mycophenolate may also have a role in treating ocular MG.
  • Other treatments for MG include plasmapheresis, intravenous immunoglobulin, and other immunosuppressive agents, but these are rarely required for ocular MG.
  • Patients should also be evaluated for thymoma.
  • Thymoma should be resected surgically.
  • Ocular MG without thymoma is not usually treated with thymectomy.

Print Article Summary Cat 2 CME Report